#3482
PANDORA-2 protocol - Intervention study to improve quality of life in patients with small (≤2 cm) non-functional pancreatic neuroendocrine tumors
Introduction:
Current guidelines changed the treatment strategy for small (≤2cm) non-functioning pancreatic neuroendocrine tumors (NF-pNET) from tumor resection to an active surveillance strategy. The previous PANDORA-1 (2021) study showed excellent clinical outcomes after a median follow-up of 17 months, where 89% of patients had pNETs without any tumor growth and only 3% of patients had tumor growth leading to a resection. Despite these results, the quality of life (QoL) was decreased at baseline and during follow-up. Furthermore, there was suboptimal adherence to the advised surveillance protocol.
Conference:
Presenting Author:
Chen J
Authors:
Chen J,
Heidsma C,
Engelsman A,
Nieveen van Dijkum E,
Keywords:
neuroendocrine,
pancreatic,
quality of life,
≤2 cm,
non-functional,
protocol,
#3048
Somatostatin Analogs or Active Surveillance in Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors
Introduction:
Non-functioning (NF), sporadic pancreatic neuroendocrine tumors (pNETs) have usually an indolent behavior, but sometimes show an unpredictable aggressiveness. Surgery is the first-choice for localized tumors >2 cm. Unresectable or metastatic lesions expressing somatostatin receptors (SSTRs) are treated with Somatostatin analogs (SSAs). No evidence of SSAs efficacy exists in tumors ≤2 cm, for which active surveillance has been proposed.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Authors:
Schinzari G,
Maiorano B,
Rossi E,
Bianchi A,
Chiloiro S,
Keywords:
pNET,
non-functioning,
sporadic,
somatostatin analogs,
surveillance,
